Target Substitution. Subject to Section 2.3.6, at any time prior to the [**] with respect to a given Initial Target or its applicable Substitute Target, Pfizer may, through written notice to Arvinas, replace such Target as further provided below. In Pfizer’s written notice, Pfizer will provide the Initial Target to be replaced and will propose a potential Substitute Target (the “Target Substitution Notice”). Arvinas will notify Pfizer in writing within [**] after the delivery of the Target Substitution Notice if the proposed Substitute Target is an Excluded Target. Otherwise, such proposed Substitute Target shall be deemed accepted by Arvinas. Provided that the proposed Substitute Target is accepted as provided above, such Substitute Target shall become a Target for all purposes under this Agreement and the replaced Initial Target or prior Substitute Target, as applicable, shall cease to be a Target for all purposes under this Agreement. [**] The Parties shall agree on the Research Plan for each Substitute Target that becomes a Target promptly following issuance of the relevant Target Substitution Notice, which Research Plan shall be substantially similar to the completed Research Plans attached to this Agreement as of the Effective Date, unless otherwise agreed in writing by the Parties.
Target Substitution. 2.8.1 During the Expansion/Substitution Period, Genentech shall have the right, at no additional cost or expense, to substitute for an Exclusive Target and designate a different Proposed Target as an Exclusive Target (“Substitute”) by providing a Substitution Notice to Arvinas in accordance with the procedures set forth under Section 2.10.2 below as follows:
Target Substitution. (a) In respect of the Licensed Targets for Option [**] (inclusive) [**], MERSANA shall have the right to substitute [**] of such Licensed Targets only, at any time prior to the earlier of (a) [**] such Licensed Target; or (b) [**] such Licensed Target (“Initial Target Substitution Right”), [**].
Target Substitution. On an Initial Target-by-Initial Target basis, at any time prior to the earlier of (a) completion of Non-GLP Toxicology Studies for the first Licensed ADC Directed to the applicable Initial Target under a Research Program, and (b) [**] following the Target Selection Date for such Initial Target (the “Proposed Substitution Deadline”), Xxxxxxx shall have the right, in its sole discretion, to substitute for such Initial Target another Reserved Antigen or other Antigen or [**] pursuant to the process set forth in this Section 3.3 (each, a “Target Substitution Right”); provided that the Proposed Substitution Deadline for the first Target Substitution Right exercised by Xxxxxxx under this Agreement shall be no later than [**] before the deadline for exercise of the Initial Target Substitution Right (as defined in the Synaffix Agreement) with respect to the applicable Initial Target under Section 2.9(a) of the Synaffix Agreement, unless the Proposed Substitute Target with respect to such Initial Target is a Non-Synaffix Target. For each Initial Target, a substitution may be made under this Section 3.3 only one time.
Target Substitution. In the event that ONO and CombiChem mutually agree in writing that the Research Target is unsuitable for further research, the Parties shall meet to discuss the substitution of another Target. If the Parties mutually agree in writing to such a ---------- *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission Target, ONO shall not be obligated to pay a second project initiation fee to CombiChem as provided in Section 8.1 hereof.
Target Substitution. At any time during the Research Term, the definition of Compound may be amended upon mutual written agreement of the Parties to provide for the substitution of a new molecular target.
Target Substitution. 2.3.1 At any time prior to the [ * ], AGT shall have the right to substitute [ * ] AGT Target with a Reserved Target Candidate in accordance with this Section 2.3 by providing a Target Substitution Notice to Licensor. If a proposed Substitute Target is deemed an AGT Target in accordance with Section 2.4, AGT shall pay one-time Substitute Target Fee to Licensor as specified in Section 7.1.3.
Target Substitution. On or before the date that is six (6) months before the end of the Discovery Program Term, but in no case more than two times in any one calendar year, Loxo may determine that research activities with respect to any one of the Amendment 5 Triage Targets should be discontinued (for example, and without limitation, because an Amendment 5 Triage Target has not yielded sufficient progress, or scientific literature suggests such Amendment 5 Triage Target is intractable or is not therapeutically relevant or for safety issues) and want to replace such Amendment 5 Triage Target with a substitute. Upon such designation, such discontinued Target shall cease to be a Target under this Agreement, and Exhibit B shall be deemed to be updated accordingly. Upon such determination by Loxo, Loxo shall provide written notice to Array of the Amendment 5 Triage Target that Loxo desires to remove from Exhibit B (each such Target, an “Identified Target”) and will include in such notification up to three (3) suggested substitutes for each such Identified Target. After receipt of such notice, Array will promptly inform Loxo whether, as of the date of such written notice, the addition of such suggested substitute target would not: (i) violate any agreement that Array has with a Third Party; (ii) add a target that is the subject of Array’s own active and ongoing research (with existing commitment and expenditure of resources for such target), was the subject of previous significant research at Array, or is the subject of drugs in Array’s clinical development pipeline or marketed product portfolio or is the subject of drugs that Array has the right to combine with drugs in its proprietary development pipeline; or (iii) add a target that Array is engaged in active, ongoing substantial negotiations (i.e., has agreed a term sheet containing material business terms) with a Third Party with respect to such target. If none of (i), (ii) or (iii) apply to any given suggested substitute target, such target shall be deemed an “Available Target”. Loxo may select the suggested substitutes for an identified Target from, among others, the potential substitutes listed on Exhibit C hereto. As of the Amendment Date, none of (i), (ii) or (iii) apply to any of the potential substitute targets listed on Exhibit C. Six months after the Amendment Date, Loxo shall eliminate at least three (3) potential substitute targets listed on Exhibit C. Twelve (12) months after the Amendment 5 Date, none of the current...
Target Substitution. Genentech shall have the right, from time to time during the Term, to substitute a different Modulator Target (or Targeting Arm, as applicable) in place of an existing Collaboration Target (each, a “Target Substitution”) solely as set forth below:
Target Substitution. Promptly following the receipt by Genentech of the Target Availability Notice for a [***], BicycleTx shall issue an invoice to Genentech for an [***], and Genentech shall pay to BicycleTx such [***] following receipt of such invoice.
